Course Director：刘宇扬

主席

主持人

讨论嘉宾

学习目标 Learning Objectives 1. 梳理心血管炎性疾病累及瓣膜损伤和心肌受累的病理机制与炎症调控规律，明确心血管全程抗炎的核心靶点、干预逻辑与分层诊疗理念。 Sort out the pathological mechanisms and inflammatory regulation patterns of valvular injury and myocardial involvement secondary to cardiovascular inflammatory diseases, and clarify the core anti-inflammatory targets, intervention logic and stratified diagnosis and treatment concepts for full-cycle cardiovascular anti-inflammatory management. 2. 剖析心肌炎、炎症性心肌病的发病机制，明确患者的临床分型、病情分层、诊疗指征与预后特点。 Dissect the pathogenesis of myocarditis and inflammatory cardiomyopathy, and define the clinical classification, disease stratification, diagnostic and therapeutic indications, as well as prognostic characteristics of relevant patients. 3. 总结CD44靶向瑞舒伐他汀脂质体递送技术的制剂优势与作用原理，明确其在钙化性主动脉瓣病中抗炎、抗钙化的干预价值与临床探索前景。 Summarize the advantages and functional mechanisms of CD44-targeted rosuvastatin liposomal delivery technology, and illustrate its intervention value in anti-inflammation and anti-calcification for calcific aortic valve disease, together with its prospects for clinical research.

讨论定位： Discission Focus: 聚焦“心血管炎性病变及瓣膜钙化疾病如何精准机制溯源、最大化心肌与脏器保护、改善远期心血管预后、靶向干预与个体化药物优化、最大化心血管全程获益”。重点讨论心血管炎性疾病从瓣膜到心肌的炎症损伤机制、心肌炎-炎症性心肌病和心衰的新型抗炎诊疗理念，同时探讨CD44靶向瑞舒伐他汀脂质体递送技术在钙化性主动脉瓣病中的创新优势与临床探索前景。 This session centers on "how to trace the precise mechanisms underlying cardiovascular inflammatory lesions and valvular calcification diseases, maximize myocardial and organ protection, improve long-term cardiovascular prognosis, implement targeted intervention and individualized drug optimization, and achieve optimal full-cycle cardiovascular benefits". Key discussion topics include the inflammatory injury mechanisms of cardiovascular inflammatory diseases ranging from valvular lesions to myocardial involvement, novel anti-inflammatory diagnosis and treatment concepts for myocarditis, inflammatory cardiomyopathy and heart failure, as well as the innovative strengths and clinical research prospects of CD44-targeted rosuvastatin liposomal delivery technology in calcific aortic valve disease.

建议讨论问题： 1.心血管炎性损伤累及瓣膜及心肌的核心驱动机制是什么，如何针对性构建精准、分层的抗炎治疗方案？ What is the core driving mechanism of cardiovascular inflammatory injury in valves and myocardium, and how to construct accurate and stratified anti-inflammatory treatment strategies accordingly? 2.现阶段心肌炎及炎症性心肌病及心衰的个体化治疗指征、随访评估指标与长期抗炎治疗风险管控应如何规范界定？ How to standardize and define the individualized treatment indications, follow-up evaluation indicators and long-term risk management of anti-inflammatory therapy for myocarditis, inflammatory cardiomyopathy, and heart failure at this stage? 3.CD44靶向瑞舒伐他汀脂质体递送技术在钙化性主动脉瓣病中，能否实现瓣膜局部精准抗炎、抗钙化并延缓瓣膜病变进展？ Can CD44-targeted rosuvastatin liposome delivery technology achieve precise local anti-inflammatory and anti-calcification effects to delay the progression of calcific aortic valve disease?

心血管炎性疾病的机制认识与抗炎方案：从瓣膜到心肌 Mechanisms and Anti-Inflammatory Strategies of Cardiovascular Inflammation: Valve to Myocardium

讨论

心肌炎-炎症性心肌病和心衰 Myocarditis, Inflammatory Cardiomyopathy and Heart Failure

讨论

CD44靶向瑞舒伐他汀脂质体递送在钙化性主动脉瓣病中的探索与进展 CD44-Targeted Rosuvastatin Liposomes for Calcific Aortic Valve Disease: Research Exploration and Progress

讨论